Author:
Kaul Grace,Shukla Manjulika,Soni Isha,Veerareddy Vaishnavi,Kumar Ravi Akunuri,Dasgupta Arunava,Srinivas Nanduri,Chopra Sidharth
Publisher
Springer Nature Singapore
Reference109 articles.
1. Achaogen Inc. (2012) A study to assess the safety, tolerability, and pharmacokinetics of ACHN-975 in healthy volunteers. https://clinicaltrials.gov/ct2/show/study/NCT01597947?term=NCT01597947&rank=1. Accessed 15 May 2022
2. Achaogen Inc. (2013) A multiple dose study to assess the safety, tolerability, and pharmacokinetics of ACHN-975 in healthy volunteers. https://clinicaltrials.gov/ct2/show/NCT01870245?term=NCT01870245&rank=1. Accessed 15 May 2022
3. Alexander MK, Miu A, Oh A et al (2018) Disrupting gram-negative bacterial outer membrane biosynthesis through inhibition of the lipopolysaccharide transporter MsbA. Antimicrob Agents Chemother 62:e01142
4. Amponnawarat A, Chompunud Na Ayudhya C, Ali H (2021) Murepavadin, a small molecule host defense peptide mimetic, activates mast cells via MRGPRX2 and MrgprB2. Front Immunol 12:2486
5. Andersen NH, Bowman J, Erwin A et al (2011) Antibacterial agents. US Patent 2011172174A1, 14 July 2011